Schündeln Michael M, Goretzki Sarah C, Hauffa Pia K, Wieland Regina, Bauer Jens, Baeder Lena, Eggert Angelika, Hauffa Berthold P, Grasemann Corinna
Department of Pediatric Hematology and Oncology, Kinderklinik III, Universitätsklinikum-Essen and the University of Duisburg-Essen, Essen, Germany.
Department of Pediatric Endocrinology and Diabetology, Kinderklinik II, Universitätsklinikum-Essen and the University of Duisburg-Essen, Essen, Germany.
PLoS One. 2014 Oct 9;9(10):e108400. doi: 10.1371/journal.pone.0108400. eCollection 2014.
Sickle cell anemia and thalassemia result in impaired bone health in both adults and youths. Children with other types of chronic hemolytic anemia may also display impaired bone health.
To assess bone health in pediatric patients with chronic hemolytic anemia, a cross-sectional study was conducted involving 45 patients with different forms of hemolytic anemia (i.e., 17 homozygous sickle cell disease and 14 hereditary spherocytosis patients). Biochemical, radiographic and anamnestic parameters of bone health were assessed.
Vitamin D deficiency with 25 OH-vitamin D serum levels below 20 ng/ml was a common finding (80.5%) in this cohort. Bone pain was present in 31% of patients. Analysis of RANKL, osteoprotegerin (OPG) and osteocalcin levels indicated an alteration in bone modeling with significantly elevated RANKL/OPG ratios (control: 0.08+0.07; patients: 0.26+0.2, P = 0.0007). Osteocalcin levels were found to be lower in patients compared with healthy controls (68.5+39.0 ng/ml vs. 118.0+36.6 ng/ml, P = 0.0001). Multiple stepwise regression analysis revealed a significant (P<0.025) influence of LDH (partial r2 = 0.29), diagnosis of hemolytic anemia (partial r2 = 0.05) and age (partial r2 = 0.03) on osteocalcin levels. Patients with homozygous sickle cell anemia were more frequently and more severely affected by impaired bone health than patients with hereditary spherocytosis.
Bone health is impaired in pediatric patients with hemolytic anemia. In addition to endocrine alterations, an imbalance in the RANKL/OPG system and low levels of osteocalcin may contribute to this impairment.
镰状细胞贫血和地中海贫血会导致成人和青少年的骨骼健康受损。患有其他类型慢性溶血性贫血的儿童也可能出现骨骼健康受损的情况。
为评估患有慢性溶血性贫血的儿科患者的骨骼健康状况,开展了一项横断面研究,纳入了45例患有不同形式溶血性贫血的患者(即17例纯合子镰状细胞病患者和14例遗传性球形红细胞增多症患者)。对骨骼健康的生化、影像学和既往史参数进行了评估。
该队列中常见25-羟基维生素D血清水平低于20 ng/ml的维生素D缺乏情况(80.5%)。31%的患者存在骨痛。对核因子κB受体活化因子配体(RANKL)、骨保护素(OPG)和骨钙素水平的分析表明,骨重塑发生改变,RANKL/OPG比值显著升高(对照组:0.08±0.07;患者组:0.26±0.2,P = 0.0007)。发现患者的骨钙素水平低于健康对照组(68.5±39.0 ng/ml对118.0±36.6 ng/ml,P = 0.0001)。多元逐步回归分析显示,乳酸脱氢酶(LDH)(偏r² = 0.29)、溶血性贫血诊断(偏r² = 0.05)和年龄(偏r² = 0.03)对骨钙素水平有显著影响(P<0.025)。与遗传性球形红细胞增多症患者相比,纯合子镰状细胞贫血患者的骨骼健康受损更为频繁和严重。
患有溶血性贫血的儿科患者骨骼健康受损。除了内分泌改变外,RANKL/OPG系统失衡和骨钙素水平低可能导致这种损害。